Lyo-Ready Genotyping Direct qPCR Blood has been optimized to provide highly specific allelic discrimination as demonstrated by excellent cluster separation, even in the presence of PCR inhibitors found in blood, serum or plasma. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC)
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cystic fibrosis screening. Clinical screening of SNPs requires large-scale multiplexed genotyping, which traditionally relies on DNA extraction from complex samples such as blood, to achieve sensitive DNA amplification. However, blood contains several PCR inhibitors that can inhibit the reaction or reduce a reaction’s efficiency.
Meridian’s Lyo-Ready Genotyping Direct qPCR Blood is a 4x inhibitor-resistant mix designed for highly specific and sensitive amplification for genotyping sequence variants, even in the presence of PCR inhibitors found in blood, serum or plasma, to give exceptional cluster resolution with clear allele discrimination, even with challenging SNP targets. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
Inhibitor tolerance to 10% whole blood, 20% plasma. Compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide and copy number variants, to give highly reproducible allelic discrimination.
Please fill out the following form about your inquiry.
